Insulin-like growth factors I and II in healthy women with and without established osteoporosis

Center for Clinical & Basic Research, Ballerup, Denmark.

We measured serum concentrations of insulin-like growth factors I and II (IGF-I and IGF-II) by radioimmunoassay in 107 healthy women aged 28-78 years and in 116 women with established osteoporosis. The women with established osteoporosis were randomized to a 1-year double-blind, placebo-controlled treatment with continuous estrogen/progestogen, anabolic steroids, salmon calcitonin or placebo and the IGFs were measured every 6 months. Women less than 35 years of age had 29% higher levels of IGF-I (p < 0.001) as compared to women above that age. For women more than 35 years of age, we found no correlation between IGF-I and age (r = 0.02). Correspondingly, we found no significant changes in serum IGF-I in 10 women, who were followed with serial measurements of IGFs every 3 months from 2 years before to 1 year after menopause; IGF-II revealed no correlation with age (r = 0.04). In the group of 116 women with established osteoporosis, IGF-I was 30% lower (p < 0.01) as compared to a group of 19 height-, weight- and age-matched nonfractured women (mean age 64 years). The IGF-II levels were equal in the two groups. Over the 1-year therapeutic intervention period, an increase in IGF-I of 13-15% (p < 0.05) was seen in the nandrolone decanoate-treated group. The same tendency was seen for hormone replacement therapy, although it was not significant. In conclusion, the serum level of IGF-I is high in young women, when peak bone mass is attained, and low in postmenopausal women with established osteoporosis.

This article has been cited by other articles:

				A. Frisoli Jr.,, P. H. M. Chaves, M. M. Pinheiro, and V. L. Szejnfeld The Effect of Nandrolone Decanoate on Bone Mineral Density, Muscle Mass, and Hemoglobin Levels in Elderly Women With Osteoporosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2005; 60(5): 648 - 653. [Abstract] [Full Text] [PDF]

				T. Ueland GH/IGF-I and bone resorption in vivo and in vitro Eur. J. Endocrinol., March 1, 2005; 152(3): 327 - 332. [Abstract] [Full Text] [PDF]

				R. A. Krajcik, N. D. Borofsky, S. Massardo, and N. Orentreich Insulin-like Growth Factor I (IGF-I), IGF-binding Proteins, and Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1566 - 1573. [Abstract] [Full Text] [PDF]

				Sibling Pair Linkage and Association Studies between Bone Mineral Density and the Insulin-Like Growth Factor I Gene Locus J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4467 - 4471. [Abstract] [Full Text]

				J. A. Langlois, C. J. Rosen, M. Visser, M. T. Hannan, T. Harris, P. W. F. Wilson, and D. P. Kiel Association Between Insulin-Like Growth Factor I and Bone Mineral Density in Older Women and Men: The Framingham Heart Study J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4257 - 4262. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				R. M. Sapolsky and E. M. Spencer Insulin-like growth factor I is suppressed in socially subordinate male baboons Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1997; 273(4): R1346 - R1351. [Abstract] [Full Text] [PDF]

				B. C. Nindl, C. R. Scoville, K. M. Sheehan, C. D. Leone, and R. P. Mello Gender differences in regional body composition and somatotrophic influences of IGF-I and leptin J Appl Physiol, April 1, 2002; 92(4): 1611 - 1618. [Abstract] [Full Text] [PDF]